Menu
MapConnectionsTopicsBulgariaThe Night (K-TRIO)Marie Skłodowska-CurieFor studentsFor teachersMethodologySurprise me
H2020Doctoral network2017–2022

PIC · Personalised In-Silico Cardiology

Horizon 2020 — Marie Skłodowska-Curie Actions

Duration
2017-09-01 → 2022-02-28
EU contribution
€4,000,569
Participants
19
Scheme
MSCA-ITN

Lines connect the coordinator with its partners.

Results in brief

Personalised In-Silico Cardiology

Cardiovascular diseases (CVD) have a huge impact on society in terms of mortality, morbidity and healthcare costs, being responsible for 1.9 million deaths in the EU annually (42% of all deaths) with a total cost of €169 billion. Improving healthcare systems in Europe in a period of ageing population and tightening financial constraints mandates a shift towards personalised and preventive management of disease. We need tailored and earlier treatments to increase the efficacy and efficiency of the healthcare system, as well as the quality of life of patients. PIC is the European ITN that trained a cohort of 15 future innovation leaders able to articulate and materialise the vision of Personalised In-silico Cardiology where healthcare is guided by in-silico models. These models become virtual reconstructions of an individual, or avatars, to evaluate current health status and therapy options. PIC fellows built both mechanistic and statistical models from clinical data (WP1), enabling the extraction of biomarkers for better diagnosis and prognosis of the individual patient. PIC fellows then applied models to maximise the value of clinical data (WP2) to inform diagnosis, and to optimise clinical devices & drug choices (WP3) to deliver a personalised therapy. The vision of a Personalised In-silico Cardiology materialised in the definition of 15 inter-related projects for each of the fellows (F1 to F15), setting the scope of the research into four main modelling aspects of the heart (anatomy, mechanics, electrophysiology, and fluid dynamics) and four cardiac conditions (heart failure, cardiomyopathies, arrhythmias and flow obstructions). The specific objectives for the project are: - WP1 focuses on the in-silico modelling technology. Its objectives are to develop the simulation methodologies, and to obtain robust biomarkers by cardiac model personalization. Interpreting clinical data through biophysical models allows the extraction of the underlying physiological parameters that best explain the data. - WP2 focuses on the data. Its objectives are to use insilico cardiac models to reduce errors in clinical data, reduce invasiveness, and to maximise its diagnostic and prognostic value. - WP3 focuses on the technologies for therapy: clinical devices and cardiac drugs. Its objective is to personalize these technologies through the adoption of the in-silico methodology and its predictions. - WP4 focuses on the clinical translation of the in-silico technology. Its objective is to evaluate in specific CVD problems the envisioned improved care through better data, diagnosis and therapies.

Data: CORDIS, © European Union

Project objective

Improving healthcare systems mandates a shift towards personalised and preventive management of disease. Specifically, the management of cardiovascular diseases has a huge impact on European society in terms of mortality, morbidity and healthcare costs, being responsible for 1.9 million deaths in the EU annually (42% of all deaths) with a total cost of €169 billion.Advances in computational and simulation technologies now provide us with unparalleled capacity to analyse clinical data in-silico, rendering the vision of an early detection of disease through model-based diagnostic biomarkers, and the design of personalised therapies through predictive models. In-silico methodologies enable the optimization of clinical protocols, from data acquisition to device parameters and intervention choices. In-silico tools also enable the reduction of animal use in the development of novel cardiac therapies and drugs. PIC is the European ITN that will train the cohort of 15 of the future innovation leaders able to articulate and materialise the vision of a Personalised In-silico Cardiology (PIC). It will address specific challenges originated by cultural and structural barriers between sectors and disciplines, articulating a fluent dialogue and work between clinicians and engineers. Fellows will be exposed to the generation of novel academic ideas, the design of practical solutions that meet actual clinical needs, the translation into industrial products, and the compliance with safety and regulation requirements. This will be achieved by pooling the expertise of leading experts from 4 academic, 3 industrial and 3 clinical beneficiaries. A highly inter-disciplinary program will be delivered in 4 research work packages, with companies leading two of them. New talent and innovation will be produced through the training in the disciplines of computational cardiac modelling, medical imaging & sensing, and clinical devices & instrumentation.

Original text from CORDIS.

Participants

  • KING'S COLLEGE LONDON · LondonCoordinatorUnited Kingdom
  • Agency for Health Quality & Assessment of Catalonia · BarcelonaSpain
  • CARDIACCS AS · OsloNorway
  • FEOPS · GentBelgium
  • FUNDACIO DE RECERCA CLINIC BARCELONA-INSTITUT D INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER · BarcelonaSpain
  • Food & Drug Administration · Silver SpringUnited States
  • GE VINGMED ULTRASOUND AS · HortenNorway
  • IBM · ArmonkUnited States
  • JANSSEN PHARMACEUTICA NV · BeerseBelgium
  • John Radcliffe Hospital · OxfordUnited Kingdom
  • MEDTRONIC BAKKEN RESEARCH CENTER B.V. · MaastrichtNetherlands
  • MS Start · ZurichSwitzerland
  • OSLO UNIVERSITETSSYKEHUS HF · OsloNorway
  • Said Business School · OxfordUnited Kingdom
  • THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD · OxfordUnited Kingdom
  • UNIVERSIDAD DE ZARAGOZA · ZaragozaSpain
  • UNIVERSITE DE BORDEAUX · BordeauxFrance
  • UNIVERSITEIT MAASTRICHT · MaastrichtNetherlands
  • VPH-Institute · LeuvenBelgium

Links

Data: CORDIS, © European Union